|
|
News Breaks
|
November 18, 2009
|
| 08:09 EDT |  | ISIS |
| theflyonthewall.com: | Isis Pharmaceuticals mipomersen benefits outweighs risks, says Needham | | After the results of the Phase 3 trial of Isis' mipomersen were presented, Needham believes that the side effects of the drug are manageable and the firm expects the drug to be approved in 1H11. Needham reiterates a Buy rating on the stock. :theflyonthewall.com |
|
|
News For ISIS From The Last 14 Days Check below for free stories on ISIS the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
